Citation Impact
Citing Papers
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Linezolid Alone or Combined with Rifampin against Methicillin-Resistant Staphylococcus aureus in Experimental Foreign-Body Infection
2008
Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin
2007
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
Colistinvs. the combination of colistin and rifampicin for the treatment of carbapenem-resistantAcinetobacter baumanniiventilator-associated pneumonia
2012
Control of Endemic Glycopeptide-Resistant Enterococci
1996
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications
2015 Standout
Molecular Characterization and Inhibition of Amanitin Uptake into Human Hepatocytes
2006
Recommendations for managing Aspergillus osteomyelitis and joint infections based on a review of the literature
2005
Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis
2006
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
2011
Natural products: An evolving role in future drug discovery
2011 Standout
Guidelines for the Management of Intravascular Catheter-Related Infections
2001
A New Equation to Estimate Glomerular Filtration Rate
2009 Standout
Tuberculosis in Patients with Human Immunodeficiency Virus Infection
1999 Standout
Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity?
2011 Standout
Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
2004 Standout
Pharmacokinetics of Antimycobacterial Drugs in Patients with Tuberculosis, AIDS, and Diarrhea
1997
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges
2019 Standout
Fluoroquinolones: Action and Resistance
2003
A review of the biomaterials technologies for infection-resistant surfaces
2013 Standout
Randomized Controlled Trial of Prophylactic Rifampin for Peritoneal Dialysis-Related Infections
1991
CONTROLLED CLINICAL TRIAL OF COMPLETE OPEN SURGICAL DRAINAGE AND OF PREDNISOLONE IN TREATMENT OF TUBERCULOUS PERICARDIAL EFFUSION IN TRANSKEI
1988
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
2001 Standout
A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future
2010 Standout
Systematic Overview of Warfarin and Its Drug and Food Interactions
2005 Standout
Models of hepatotoxicity and the underlying cellular, biochemical and immunological mechanism(s): A critical discussion
2013
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Enzyme induction in the cytochrome P-450 system
1990 Standout
Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials
2001
Cytochrome P450 ω-Hydroxylase Pathway of Tocopherol Catabolism
2002 Standout
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
Inhibition and induction of human cytochrome P450 (CYP) enzymes
1998
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
2017 StandoutNobel
New approaches for treating staphylococcal biofilm infections
2011
How antibiotics kill bacteria: from targets to networks
2010 Standout
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
2015
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Candida Infections of Medical Devices
2004 Standout
Serum Concentrations of Rifampin, Isoniazid, and Intestinal Absorption, Permeability in Patients with Multidrug Resistant Tuberculosis
2009
Primary Biliary Cirrhosis
1987 Standout
In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus
2008
Antibiotics and Bacterial Resistance in the 21st Century
2014 Standout
Guidelines on the Diagnosis and Management of Pericardial Diseases Executive SummaryThe Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology
2004 Standout
Primary Biliary Cirrhosis
2011 Standout
Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa
2015
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
Interaction of Chronic Daily Warfarin Therapy and Rifampin
1975
Adverse reactions to first-line antituberculosis drugs
2006
History of the Development of Rifampin
1983
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines
2012
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation
2016 StandoutNobel
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of Americaa
2012 Standout
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
1980 Standout
Interaction of Ketoconazole with Rifampin and Isoniazid
1984
Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption
2008
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings
2007 Standout
Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease
2004
Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks
1997 Standout
Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis
1985
Subcellular Partitioning and Intramacrophage Selectivity of Antimicrobial Compounds against Mycobacterium tuberculosis
2017 StandoutNobel
Clinical Implications of Enzyme Induction and Enzyme Inhibition
1981
Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J-774: Ultrastructure and drug-susceptibility studies
1987
Interaction of Sodium Warfarin and Rifampin
1974
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
2008 Standout
Serum Creatinine as an Index of Renal Function: New Insights into Old Concepts
1992 Standout
Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB
2017 StandoutNobel
A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients
2012
The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.
2001
Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections
1985
Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia
1993
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
2003 Standout
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
2020 Standout
Hematological Problems in Pediatric Intensive Care
2013 Standout
Guidelines for the Management of Intravascular Catheter-Related Infections
2001
Drug Prescribing in Renal Failure: Dosing Guidelines for Adults.
1988
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus
1990
Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
2015 Standout
Works of G Acocella being referenced
Comparative Bioavailability of Isoniazid, Rifampin, and Pyrazinamide Administered in Free Combination and in a Fixed Triple Formulation Designed for Daily Use in Antituberculosis Chemotherapy: II. Two-Month, Daily Administration Study
1988
Comparative Bioavailability of Isoniazid, Rifampin, and Pyrazinamide Administered in Free Combination and in a Fixed Triple Formulation Designed for Daily Use in Antituberculosis Chemotherapy: I. Single-Dose Study
1988
The penetration of rifampicin, pyrazinamide, and pyrazinoic acid into mouse macrophages.
1985
Pharmacokinetics and Metabolism of Rifampin in Humans
1983
The Effect of an Intravenous Infusion of Rifamycin SV on the Excretion of Bilirubin, Bromsulphalein, and Indocyanine Green in Man
1965
Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination.
1985
Human bioavailability studies.
1989
Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration study.
1985
CAN RIFAMPICIN USE BE SAFELY EXTENDED?
1977
Interaction of rifampicin with other drugs
1980
Clinical Pharmacokinetics of Rifampicin
1978
Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
1993
Kinetic Studies on Rifampicin
1971
Kinetic studies on rifampicin
1972
Evidence that rifampicin can be used safely for non-tuberculous diseases.
1980
Pharmacokinetic study on intravenous rifampicin in man
1984
Serum concentrations and biliary excretion of bilirubin during short-term treatment with rifampicin.
1973